Welcome to our dedicated page for Kalaris Therapeutics news (Ticker: KLRS), a resource for investors and traders seeking the latest updates and insights on Kalaris Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kalaris Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kalaris Therapeutics's position in the market.
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will engage in a Fireside Chat on Tuesday, May 27th, 2025, at 8:00 AM ET. A replay of the event will be available on the company's Investor Relations webpage.
Kalaris Therapeutics (NASDAQ: KLRS) reported its Q1 2025 financial results and provided business updates. The company is advancing its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). Initial clinical data is expected in Q4 2025.
Financial highlights include cash and cash equivalents of $101.0 million as of March 31, 2025, up from $1.6 million in December 2024, primarily due to the AlloVir merger. The company reported a net loss of $10.2 million ($2.52 per share) compared to $3.4 million ($2.60 per share) in Q1 2024. R&D expenses increased to $6.0 million from $2.0 million, while G&A expenses rose to $4.3 million from $0.6 million year-over-year.
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, has appointed Leone Patterson to its Board of Directors and as Chair of the Board's Audit Committee. Patterson currently serves as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks, managing corporate finance, business development, and operations.
Patterson brings extensive biotech industry experience, having previously held leadership positions at Tenaya Therapeutics as Chief Financial and Business Officer, and at Adverum Biotechnologies as CFO, President, CEO, and Director. Her career includes senior finance roles at Diadexus, Transcept, Exelixis, Novartis, and Chiron, as well as experience in KPMG's audit practice. She holds a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Mary's College.
Kalaris Therapeutics (NASDAQ: KLRS) has completed its merger with AlloVir, with shares set to trade on Nasdaq from March 19, 2025. The company's focus is on developing TH103, a novel anti-VEGF treatment for retinal diseases, specifically engineered to address limitations in current neovascular Age-related Macular Degeneration (nAMD) therapies.
The clinical-stage biopharmaceutical company's lead candidate has shown promising preclinical results with potent anti-VEGF activity and sustained ocular residence time. Initial data from Part 1 of the ongoing Phase 1 trial in nAMD patients is expected in H2 2025.
Following the merger, Kalaris has approximately $100 million in cash and cash equivalents, projected to fund operations into Q4 2026, extending beyond the planned Phase 2 clinical trial initiation.
FAQ
What is the current stock price of Kalaris Therapeutics (KLRS)?
What is the market cap of Kalaris Therapeutics (KLRS)?
